Genomics England has selected Cognizant as a technology partner to help design and implement the IT operating environment for the 100,000 Genomes Project

Digitising medical records supports personalised medicine

Genomics England, a wholly owned company of the Department of Health, has selected Cognizant as a technology partner to help design and implement the IT operating environment for the 100,000 Genomes Project

The 100,000 Genomes Project will sequence 100,000 whole genomes from NHS patients and their families.

Cognizant said the project aims to enable scientific discovery, medical insights and diagnostics so that the NHS will be able to offer personalised treatments to patients with conditions that are currently hard to treat.

David Brown, head of informatics infrastructure, Genomics England, said: “Combining genomic sequence data with medical records is a ground-breaking initiative. Researchers will study how best to use genomics in healthcare and interpret the data to help patients.”

As part of a two-year agreement, Cognizant will help provide end-to-end systems integration and analytics services for the technology platform built by Genomics England.

This will enable Genomics England to augment its capability and capacity to process samples and interpret findings.

Bhaskar Sambasivan, vice president of Cognizant’s Life Sciences practice said: “Large-scale sequencing initiatives like the UK’s 100,000 Genomes Project require a flexible, secure operating platform to help drive innovation in new diagnostic and treatment options for patients and healthcare providers.”

Brown, Genomics England, said: “We selected Cognizant for its extensive life sciences capabilities, knowledge of research, management and analysis of clinical data sets, and experience in working with the UK public sector organisations.”



'Digitising medical records supports personalised medicine' has no comments

Be the first to comment this post!

Would you like to share your thoughts?

Your email address will not be published.

© 2017 Rapid Life Sciences Ltd, a Rapid News Communications Group Company. All Rights Reserved.

Privacy policy

Terms and conditions